BillionToOne, a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces it has secured an additional $48.5 million of funding from existing equity investors as well as upsized its Term Loan Facility with access to up to $35 million, with its existing lender, Bridge Bank. With this additional funding, the Company has raised over $280 million since its first commercial product launch just three years ago. The $48.5M funding consists of additional investments from Series C investors including Libertus Capital, Hummingbird Ventures, Baillie Gifford, Adams Street Partners, Neotribe Ventures, Fifty Years VC, Norwest Venture Partners, and Time BioVentures.

BillionToOne is a next-generation molecular diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The Company's Quantitative Counting Templates, QCTs, enable counting DNA molecules at the single-count level with single base-pair precision. BillionToOne was co-founded by Oguzhan Atay, Ph.D., and David Tsao, Ph.D.